Evidence map›Paper›PMID 25772174›Full record

ReviewEndocrine, metabolic & immune disorders drug targets2015

Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect.

Yoshifumi Saisho

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Endocrine, metabolic & immune disorders drug targets, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 243 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
243citing papers in PubMed, 4 pooled it
12.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03774108 phase4unknown statusstarted 2018, after this paper: background citation

Metformin Administration Effect Over Systemic Inflammation Serum Markers in HIV Positive Prediabetic Patients

Ran2018Enrolled40Registered outcomes1Posted comparisons0ConditionsHIV-1-infection, PrediabetesArmsMetformin Hydrochloride 850 MG, Placebo
PMID 29773933PMID 27766258PMID 27058351other papers from this trial
Open the trial in the graph
NCT07588932 early_phase1recruitingnot on this mapstarted 2026, after this paper: background citation

Relying on Pharmacotherapy to Improve Motor Gains of Robot-Assisted Upper-Extremity Rehabilitation in Chronic Stroke Survivors

TypeinterventionalSponsorSpaulding Rehabilitation HospitalRan2026 to 2028Enrolled50ConditionsStrokeArmsTelmisartan, Metformin, Cilostazol
3 · Its place in the literature

Who cites it

243 citing papers in PubMed, 4 syntheses or guidelines pooled it, 445 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Preventing Long COVID With Metformin.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  20. Article

183 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Yoshifumi SaishoDepartment of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjukuku, Tokyo 160-8582, Japan. ysaisho@z5.keio.jp.
Keio University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metformin is an oral hypoglycemic agent which is most widely used as first-line therapy for type 2 diabetes. Metformin improves hyperglycemia by suppressing hepatic glucose production and increasing glucose uptake in muscle. Metformin also has been shown to reduce cardiovascular events in randomized controlled trials; however, the underlying mechanism remains to be established. Recent preclinical and clinical studies have suggested that metformin not only improves chronic inflammation through the improvement of metabolic parameters such as hyperglycemia, insulin resistance and atherogenic dyslipidemia, but also has a direct anti-inflammatory action. Studies have suggested that metformin suppresses inflammatory response by inhibition of nuclear factor κB (NFκB) via AMP-activated protein kinase (AMPK)-dependent and independent pathways. This review summarizes the basic and clinical evidence of the anti-inflammatory action of metformin and discusses its clinical implication.

Indexed as

AnimalsAnti-Inflammatory AgentsDiabetes Mellitus, Type 2GlucoseHumansHyperglycemiaHypoglycemic AgentsInflammationMetforminTreatment OutcomeAnti-Inflammatory AgentsGlucoseHypoglycemic AgentsMetformin

Identifiers

PMID25772174
OpenAlexW185214937

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.